These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 15234232)

  • 1. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
    Harpio R; Einarsson R
    Clin Biochem; 2004 Jul; 37(7):512-8. PubMed ID: 15234232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
    Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
    Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
    Brouard M; Quillien V; Ollivier I; Lesimple T; Adamski H; Chevrant-Breton J
    Ann Dermatol Venereol; 2000 Jan; 127(1):56-9. PubMed ID: 10717564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of S100B protein in neoplasms and other diseases].
    Bánfalvi T; Gergye M; Beczássy E; Gilde K; Ottó S
    Magy Onkol; 2004; 48(1):71-4. PubMed ID: 15105899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma.
    Bolander A; Agnarsdóttir M; Wagenius G; Strömberg S; Pontén F; Ekman S; Brattström D; Larsson A; Einarsson R; Ullenhag G; Hesselius P; Bergqvist M
    Melanoma Res; 2008 Dec; 18(6):412-9. PubMed ID: 19011512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
    Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
    J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH.
    Egberts F; Pollex A; Egberts JH; Kaehler KC; Weichenthal M; Hauschild A
    Onkologie; 2008 Jul; 31(7):380-4. PubMed ID: 18596385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients.
    Faries MB; Gupta RK; Ye X; Lee C; Yee R; Leopoldo Z; Essner R; Foshag LJ; Elashoff D; Morton DL
    Cancer Invest; 2007 Aug; 25(5):285-93. PubMed ID: 17661202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
    Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum markers in skin melanoma--preliminary study.
    Dumitraşcu G; Constantin C; Manda G; Hristescu S; Mărgaritescu I; Chiriţă D; Neagu M
    Roum Arch Microbiol Immunol; 2009; 68(3):125-35. PubMed ID: 20361532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma.
    Garnier JP; Letellier S; Cassinat B; Lebbé C; Kerob D; Baccard M; Morel P; Basset-Seguin N; Dubertret L; Bousquet B; Stoitchkov K; Le Bricon T
    Eur J Cancer; 2007 Mar; 43(4):816-21. PubMed ID: 17276671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients.
    Vereecken P; Awada A; Suciu S; Castro G; Morandini R; Litynska A; Lienard D; Ezzedine K; Ghanem G; Heenen M
    Melanoma Res; 2009 Oct; 19(5):316-20. PubMed ID: 19581819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma.
    Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E
    Melanoma Res; 2000 Jun; 10(3):237-41. PubMed ID: 10890377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
    Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
    J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MIA as a reliable tumor marker in the serum of patients with malignant melanoma.
    Stahlecker J; Gauger A; Bosserhoff A; Büttner R; Ring J; Hein R
    Anticancer Res; 2000; 20(6D):5041-4. PubMed ID: 11326664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients.
    Weinlich G; Murr C; Richardsen L; Winkler C; Fuchs D
    Dermatology; 2007; 214(1):8-14. PubMed ID: 17191041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Laboratory markers of melanoma progression].
    Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J
    Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of serum analyses of S-100 protein beta in malignant melanoma.
    Hansson LO; von Schoultz E; Djureen E; Hansson J; Nilsson B; Ringborg U
    Anticancer Res; 1997; 17(4B):3071-3. PubMed ID: 9329604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S100B protein expressions as an independent predictor of early relapse in UICC stages II and III colon cancer patients after curative resection.
    Hwang CC; Chai HT; Chen HW; Tsai HL; Lu CY; Yu FJ; Huang MY; Wang JY
    Ann Surg Oncol; 2011 Jan; 18(1):139-45. PubMed ID: 20628824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.